NEW YORK (GenomeWeb News) – German biomarker firm Pronota today announced a deal with Molecuence for the discovery and validation of stroke biomarkers.
Pronota will use its MASStermind protein biomarker platform for the discovery stage of the deal, and its MASSterclass technology for the verification work.
Financial and other terms of the deal were not disclosed.
Molecuence, headquartered in Yokohama, Japan, is a wholly owned subsidiary of Mitsubishi Chemical and develops disease biomarkers.